[{"data":1,"prerenderedAt":78},["ShallowReactive",2],{"story-8245-tw":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":16,"questions":17,"relatedArticles":30,"body_color":76,"card_color":77},"8245",null,"減重革命：GLP-1藥物如何重塑消費者健康與食品市場","藥物創新正推動營養、肥胖管理和食品產業策略的巨大變革",[],[10,11,12,13,14,15],"https://cf-images.us-east-1.prod.boltdns.net/v1/static/694940094001/26d48009-6c0c-4b8e-8ab0-d2882aecd13f/a2f88b5f-01d4-4699-8469-88323a3dfa5e/1280x720/match/image.jpg","https://cdn.sanity.io/images/0vv8moc6/hcplive/2f6975c80bbc61f4e0e931c8344cf0985cac952c-1200x628.png","https://www.reuters.com/resizer/v2/RN6IGSJGARNMDL3YBVF6C2AS5M.jpg?auth=a78bdb5389037be24c140aece2f39716ff3f8c94384958a3fa3e71c91ae6d19c&height=628&width=1200&quality=80&smart=true","https://images.mktw.net/im-31158963?width=1260&height=840","https://images.wsj.net/im-06695753?width=700&height=511","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/igsbG9OKkBJg/v0/-1x-1.webp","**減重藥物市場**正經歷深刻轉變，**GLP-1藥物**崛起成為重塑消費者健康和產業動態的關鍵力量。這場革命的核心是諾和諾德在2023年12月獲得FDA批准的口服**Wegovy**減肥藥丸，這標誌著肥胖藥物可及性方面取得重大突破。\n\n**製藥創新正與消費者健康趨勢碰撞**，創造出一個複雜的機會生態系統。美國成年人中約有40%被歸類為肥胖，目前僅有12%的人使用GLP-1藥物，市場潛力巨大。康奈爾大學的一項研究揭示了一個引人入勝的經濟漣漪效應：使用這些藥物的家庭減少了5.3%的雜貨支出和8%的速食支出，這表明消費者行為正在發生深刻的結構性變化。\n\n競爭格局非常激烈，**禮來和諾和諾德**正在推動快速創新。一項2025年的頭對頭研究表明，禮來的**Zepbound**比Wegovy更有效，突顯了這場在主導這個新興市場的激烈製藥競賽。這場競爭不僅僅是關於減重——這些藥物顯示出治療多種健康狀況的潛力，將其戰略價值擴展到遠超最初預期的範圍。\n\n對於食品行業的參與者來說，影響是深遠的。像**康尼格拉**和**達能**這樣的公司已經開始調整，推出了“GLP-1友好”的產品線，包括高蛋白、小份量的產品。電子商務和食品銷售商必須迅速發展他們的策略，開發專門的營養產品、補充劑和膳食替代品，以迎合這個新興的消費群體。\n\n從注射劑到口服藥物的轉變不僅代表著技術上的里程碑，也表明了對個性化營養和醫療干預的根本性重新構想。隨著製藥公司繼續投資於更容易獲得的治療方案，我們正在見證一場潛在的醫療保健和飲食革命的早期階段，這可能從根本上改變我們應對肥胖、營養和代謝健康的方式。",[18,21,24,27],{"title":19,"answer":20,"author":5,"avatar":5,"time":5},"GLP-1藥物如何改變消費者的支出模式？","研究顯示，使用 GLP-1 藥物的家庭，其雜貨支出減少 5.3%，速食支出則減少 8%。這表明飲食習慣發生了顯著變化，消費者可能購買較少但營養密度更高的食品，以配合藥物的代謝效應。",{"title":22,"answer":23,"author":5,"avatar":5,"time":5},"食品公司在 GLP-1 藥物市場中有哪些機會？","食品公司可以開發專門的「GLP-1友善」產品線，主打高蛋白質、小份量供應。潛在的機會包括營養補充品、代餐，以及能輔助這些藥物代謝效應的特定食品。",{"title":25,"answer":26,"author":5,"avatar":5,"time":5},"從注射劑轉向口服減重藥物，為何意義重大？","轉用口服藥物可提升可及性，並降低治療障礙。它使減重藥物更為便利，可能藉此擴大市場，吸引先前因注射需求而猶豫不決的患者。這可能會大幅提高藥物採用率。",{"title":28,"answer":29,"author":5,"avatar":5,"time":5},"藥廠如何在減肥藥市場中競爭？","禮來 (Eli Lilly) 和諾和諾德 (Novo Nordisk) 等公司正參與一場創新競賽，進行直接比對療效研究，並開發更方便的用藥形式。 這種競爭正在推動藥物療效、給藥方式和潛在治療應用（超越減重）的快速進展。",[31,36,40,45,49,53,57,60,64,68,72],{"id":32,"title":33,"source":34,"logo":5,"time":35},146126,"Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill","https://finance.yahoo.com/news/stock-market-today-dec-23-220218802.html","3天前",{"id":37,"title":38,"source":39,"logo":14,"time":35},146125,"Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy","https://www.wsj.com/health/pharma/novo-nordisk-shares-jump-after-fda-approves-pill-version-of-wegovy-0c759799?gaa_at=eafs&gaa_n=AWEtsqel-eVXrL_rj-IN8G_cjy7fElhWoEt6usE9ZlSQ8h03DLlVKyI9x3rs&gaa_ts=694c859d&gaa_sig=b4_qrEVA3ULaMO8gCO_mHOIkyWE4gbJG4Zs4NgiHSbFrSZ8fUr8MqImJvxCmsFpzFmdgQgr1aGNwvzfO2eg2DQ%3D%3D",{"id":41,"title":42,"source":43,"logo":15,"time":44},146147,"Weight-Loss Drugs Are Changing. Here’s What to Know","https://www.bloomberg.com/news/articles/2025-12-24/weight-loss-drugs-are-changing-what-to-know-about-glp-1-medications","2天前",{"id":46,"title":47,"source":48,"logo":13,"time":35},146124,"Novo Nordisk first out of the gate with oral weight-loss drug, and its stock jumps","https://www.marketwatch.com/story/novo-nordisk-first-out-of-the-gate-with-oral-weight-loss-drug-and-its-stock-jumps-cd7c97ef?gaa_at=eafs&gaa_n=AWEtsqe2tzZQqd71F_wQ-ybcRVYa-rrKwlk4FNTO50Rtk4B6rKriZKj8dN6l&gaa_ts=694c859d&gaa_sig=7RkNngNu3qT2MpBYfqc5Ry50Qbmr4N-7XSnAHKy75RdK31lWDujkZwv8hRrYTGlG2fnK9I3svgsyQKLabuU0lg%3D%3D",{"id":50,"title":51,"source":52,"logo":12,"time":44},146146,"Weight-loss pill approval set to accelerate food industry product overhauls","https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-pill-approval-set-accelerate-food-industry-product-overhauls-2025-12-24/",{"id":54,"title":55,"source":56,"logo":10,"time":44},146119,"FDA approves first GLP-1 pill for weight loss","https://www.foxnews.com/video/6386914863112",{"id":58,"title":51,"source":59,"logo":5,"time":44},146118,"https://finance.yahoo.com/news/weight-loss-pill-approval-set-110241555.html",{"id":61,"title":62,"source":63,"logo":5,"time":35},146123,"Why Novo Nordisk Stock Popped Today","https://finance.yahoo.com/news/why-novo-nordisk-stock-popped-222328022.html",{"id":65,"title":66,"source":67,"logo":5,"time":44},146122,"NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?","https://finance.yahoo.com/news/nvos-first-oral-obesity-pill-154900283.html",{"id":69,"title":70,"source":71,"logo":5,"time":44},146121,"ACT Brief: FDA Approval of Oral Wegovy, 2025’s Most-Read ACT Coverage, and Data Quality as the Foundation for AI","https://www.appliedclinicaltrialsonline.com/view/fda-approval-oral-wegovy-2025-most-read-act-coverag-data-quality-foundation-ai",{"id":73,"title":74,"source":75,"logo":11,"time":44},146120,"Oral Semaglutide and the Future of GLP-1 Obesity Treatment, With Timothy Garvey, MD","https://www.hcplive.com/view/oral-semaglutide-and-the-future-of-glp-1-obesity-treatment-with-timothy-garvey-md","#b92d65ff","#b92d654d",1766795267950]